RxDoctor Payments DataLook up a doctor →

Kenneth Barngrover, DO

Interventional Pain Medicine · Columbus, GANPI 1588787162

Payments from drug & device makers

$11,749in general payments, 2019–2025

Across 522 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Collegium Pharmaceutical, Inc.$2K
  • Merz North America, Inc.$2K
  • Boston Scientific$928
  • Scilex Pharmaceuticals Inc.$831
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$734
  • plus $2K from 31 others

What the payments were for

  • Speaking & faculty fees$2,40020%
  • Food & beverage$9,28179%
  • Education$681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,749 in reported general payments places this provider in the 75th percentile of 129 interventional pain medicine providers in Georgia.

See all interventional pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$451,998
Medicare patients
345
Services billed
8,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PercocetOxycodone Hcl/Acetaminophen23$120,614
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen3,117$110,826
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen3,289$102,718
Xtampza ErOxycodone Myristate127$88,311
OxycontinOxycodone Hcl109$84,402
BelbucaBuprenorphine Hcl101$74,765
Buprenorphine149$51,641
ZtlidoLidocaine36$38,893
Nurtec OdtRimegepant Sulfate21$36,087
Morphine Sulfate ErMorphine Sulfate810$32,347
Fentanyl219$23,708
UbrelvyUbrogepant20$22,863
NucyntaTapentadol Hcl12$22,315
LinzessLinaclotide23$15,461
BelsomraSuvorexant33$14,613

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta$1,556$185,391240 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$96$58,077410 claims
Scilex Pharmaceuticals Inc.Ztlido$831$38,89336 claims
AbbVieUbrelvy, Linzess$3,805$38,32443 claims
PfizerNurtec Odt$401$36,08721 claims
MerckBelsomra$213$14,61333 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 129 interventional pain medicine providers in Georgia.

Other interventional pain medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →